Understanding the Continuum of Clinical Collaboration

As biopharmaceutical companies evaluate strategies to advance their products to market, they are increasingly doing so with new options for partnership. Contract Research Organization (CRO) or vendor partners are invited to solve challenges of capacity, quality, expertise and infrastructure – but not necessarily all at the same time. For one clinical team, short-term monitoring capacity in Asia is needed where the group has none; for another, in an established geography, more medical expertise in a newly-acquired therapy area will improve critical site relationships; in a third part of the same organization, drug safety leaders tackle fluctuating volumes that stress their ability to remain compliant. All of this under corporate pressure to raise research productivity without sacrificing quality.